China
Africa
Explore chapters and articles related to this topic
Terpenes and Terpenoids
Published in William J. Rea, Kalpana D. Patel, Reversibility of Chronic Disease and Hypersensitivity, Volume 4, 2017
William J. Rea, Kalpana D. Patel
At the EHC-Dallas and the EHC-Buffalo, we have treated over 7000 patients with avoidance and injections with the neutralizing doses for terpenes without problems. The average duration of therapy is 1–1 1/2 years. Patients usually take the injections every 4 days. On greater exposure, they may take up to four injections per day, although the extract from the average exposure has been found to be extremely effective.
Biomaterial-Based Particulate Drug Carriers
Published in Dan Peer, Handbook of Harnessing Biomaterials in Nanomedicine, 2021
Retention at the target: The carrier should obviously remain at the target for a sufficient time span to release its drug load. This time span could be short or long depending on the needs of the specific therapy.
Sex differences in 123I-mIBG scintigraphy imaging techniques in patients with heart failure
Published in Expert Review of Medical Devices, 2023
Miriam Conte, Maria Silvia De Feo, Viviana Frantellizzi, Arianna Di Rocco, Alessio Farcomeni, Flaminia De Cristofaro, Ricci Maria, Antonio Rosario Pisani, Giuseppe Rubini, Giuseppe De Vincentis
We retrospectively valued in our Institution 306 patients with HF who experienced or had not experienced AE, where AE was considered episodes of sustained ventricular tachycardia superior to 30 s, anti-tachycardiac pacing or defibrillation, resuscitated cardiac arrest or sudden cardiac death (SCD). Patients with NYHA class II or III, left ventricular ejection fraction (LVEF) <35%, the presence of indication for an ICD implantation as primary or secondary prevention, with an expected survival >1 year, an age major of 18 years old and which signed informed consent were included. All patients followed optimal medical therapy, as described in international current guidelines [20]. Patients with previous ICD implantation, cardiac resynchronization therapy (CRT) indication, oncological history, and severe valvopathy, which suffered acute coronary syndrome less than 3 months or had a contraindication to ICD implantation, were excluded. All patients underwent 123I-mIBG scintigraphy 7–15 days before ICD implantation and evaluation of the results was performed after an 85-month follow-up. The study protocol obtained the approval of the institutional committee on human research and respected the ethical guidelines of the 1975 Helsinki Declaration.
Effect of congestive heart failure on safety and efficacy of left atrial appendage closure in patients with non-valvular atrial fibrillation
Published in Expert Review of Medical Devices, 2022
Mingzhong Zhao, Cody R. Hou, Jianlin Bai, Felix Post, Jens Walsleben, Nora Herold, Juan Yu, Zufeng Zhang, Jiangtao Yu
According to AF management guidelines, prevention of thromboembolism should be performed in subjects with AF who have a history of prior stroke, TIA, or a CHA2DS2-VASc score of 2 or greater [3]. Both traditional oral anticoagulant (OAC) – warfarin and direct oral anticoagulants (DOACs), including the direct thrombin inhibitor and the factor Xa inhibitors, have been used for the prophylaxis of thromboembolism [3]. DOACs demonstrated more favorable efficacy and safety profiles, with lower risks of hemorrhage and mortality among AF patients compared with warfarin [4]. However, patients taking either warfarin or DOACs are still at risk of bleeding. Furthermore, OAC therapy was not suitable in special populations, such as those with higher risk of major bleeding or advanced chronic kidney disease (CKD) [5].
Methods and strategies of tDCS for the treatment of pain: current status and future directions
Published in Expert Review of Medical Devices, 2020
Kevin Pacheco-Barrios, Alejandra Cardenas-Rojas, Aurore Thibaut, Beatriz Costa, Isadora Ferreira, Wolnei Caumo, Felipe Fregni
To date, to receive this treatment, patients need to commute daily to the specialized centers, which disrupts their commitments and this factor also increases healthcare’s cost. However, given the current COVID-19 situation, chronic pain population has been affected in receiving treatment and increasing pain from external factors stress and anxiety [152]. Brocalero-Camacho et al. (2020) [153] explains the effects of discontinue tDCS sessions in chronic pain patients, highlighting the importance of a potential home-based therapy. For a safe treatment with tDCS at home, the device needs to present some safety characteristics, such as for example, a blocked system to guarantee the dosage and prevent overuse. In addition, it is essential that users cannot change electrode positions, and the device software should register the impedance contact and interrupts the session if the impedance exceeds a value determined. In addition, ideal equipment for home-based tDCS at home needs to track the time that current circulated between the electrodes to assess the adhesion to treatment. The equipment needs to be an easy handle -device to self-application to permit flexible schedule to apply the therapy according to the personal schedule. Above all, the device should be tested in studies with good methodological quality to guarantee that the tool offers effective treatment. It needs to stress that this therapy approach should be prescribed by a health professional with knowledge on neurobiological processes and based on medical diagnosis to guarantee the best stimulation parameters and the appropriate areas to be stimulated.